Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. The Company’s lead ca...
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, medulloblastoma and paediatric diffuse midline glioma.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.